Pegaspargase
 | |
| Names | |
|---|---|
| Pronunciation | /pəˈɡæspərɡeɪz/ |
| Trade names | Oncaspar |
| |
| Clinical data | |
| Main uses | Acute lymphoblastic leukemia (ALL)[1] |
| Side effects | Allergic reactions, blood clotting problems, high blood sugar, liver problems, pancreas inflammation, blood clots in the brain[2] |
| Pregnancy category |
|
| Routes of use | Intramuscular injection (IM), intravenous (IV) |
| Defined daily dose | Not established[3] |
| External links | |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a695031 |
| Legal | |
| License data |
|
| Legal status |
|
| Chemical and physical data | |
| Formula | C1377H2208N382O442S17 |
| Molar mass | 31732.06 g·mol−1 |
Pegaspargase, sold under the trade name Oncaspar, is a medication used in the treatment of acute lymphoblastic leukemia (ALL).[1] Often it is used together with anthracycline, vincristine, and prednisone.[2] It is used by injection.[2]
Common side effects include allergic reactions, blood clotting problems, high blood sugar, liver problems, pancreas inflammation, and blood clots in the brain.[2] Its use during pregnancy may harm the baby.[4] It is a modified version of the enzyme asparaginase which has undergone PEGylation.[5][2] It works by breaking down asparagine, decreasing its availability to make protein.[2]
Pegaspargase was approved for medical use in the United States in 1994.[2] It is on the World Health Organization's List of Essential Medicines.[6] It is made by Sigma-Tau.[2] In the United States it costs about $US17,800 per 3,750 units vial.[7]
Dosage
The defined daily dose is not established.[3]
References
- ↑ 1.0 1.1 Graham ML (2003). "Pegaspargase: a review of clinical studies". Adv. Drug Deliv. Rev. 55 (10): 1293–302. doi:10.1016/S0169-409X(03)00110-8. PMID 14499708.
- ↑ 2.0 2.1 2.2 2.3 2.4 2.5 2.6 2.7 "Pegaspargase Monograph for Professionals". Drugs.com. Archived from the original on 17 August 2019. Retrieved 11 October 2019.
- ↑ 3.0 3.1 "WHOCC - ATC/DDD Index". www.whocc.no. Archived from the original on 25 November 2020. Retrieved 9 September 2020.
- ↑ "Pegaspargase (Oncaspar) Use During Pregnancy". Drugs.com. Archived from the original on 11 October 2019. Retrieved 11 October 2019.
- ↑ "UNM Cancer Center". Archived from the original on 3 September 2006. Retrieved 28 August 2007.
- ↑ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- ↑ "Oncaspar Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 13 May 2020. Retrieved 11 October 2019.
External links
| External sites: | |
|---|---|
| Identifiers: |
|
 | This antineoplastic or immunomodulatory drug article is a stub. You can help MDWiki by expanding it. |
- Pages using duplicate arguments in template calls
- Use dmy dates from September 2019
- Articles with invalid date parameter in template
- Chemical articles with unknown parameter in Infobox drug
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Drug has EMA link
- Drugboxes which contain changes to verified fields
- Chemicals that do not have a ChemSpider ID assigned
- Antineoplastic drugs
- Takeda Pharmaceutical Company brands
- World Health Organization essential medicines
- RTT
- All stub articles
- Antineoplastic and immunomodulating drug stubs